Aspire Biopharma Holdings (ASBP) Non-Current Assets (2022 - 2026)

Aspire Biopharma Holdings (ASBP) has reported Non-Current Assets for 4 consecutive years, with $75000.0 the latest figure, recorded in Q2 2026.

• On a quarterly basis, Non-Current Assets changed N/A year-over-year to $75000.0 in Q2 2026; TTM through Jun 2026 was $75000.0, a 98.85% decrease from a year earlier, with the FY2023 full-year figure at $19.9 million, down 93.35% from the prior year.
• Non-Current Assets was $75000.0 for Q2 2026 at Aspire Biopharma Holdings, down from $6.5 million in the prior quarter.
• Over five years, Non-Current Assets peaked at $302.2 million in Q1 2023 and troughed at $75000.0 in Q2 2026.
• A 4-year average of $143.2 million and a median of $20.1 million in 2024 frame the typical range for Non-Current Assets.
• The widest YoY moves for Non-Current Assets: up 2.36% in 2023, down 93.38% in 2023.
• Over 4 years, Non-Current Assets stood at $299.1 million in 2022, then slumped by 93.35% to $19.9 million in 2023, then slumped by 67.21% to $6.5 million in 2024, then plunged by 98.85% to $75000.0 in 2026.
• The last three Non-Current Assets figures came in at $75000.0 (Q2 2026), $6.5 million (Q2 2024), and $20.1 million (Q1 2024), per Business Quant data.